Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epirubicin DEB-TACE with or without tocilizumab for stage III hepatocellular carcinoma
ChiCTR2100044103Phase 4Recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of epirubicin and tocilizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Tumor-free survival. Started Dec 2020; status: recruiting.
02
Drugs
epirubicintocilizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100044103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044103.